Insulin-like growth factor 1

Insulin-like growth factor 1 has been studied in 99 papers since 1989: 2 trials and 13 observational studies in people, 38 in animals, 8 in cells, 37 reviews; 14 in the past year. Its furthest trials in people are at phase 2. The newest story, Oct 2, 2026: “IGF-1 and SLC25A33 preserve cochlear blood barrier integrity in aged mice”.

InterventionPhase 2

99 papers study it100 findingsUpdated

Research on it is growing about as fast as aging research as a whole: 44 papers in the latest year counted

1 new paper in 30 daysSee all 99 papers on insulin-like growth factor 1

At a glance

Insulin-like growth factor 1 extends lifespan in one study of Zmpste24(-/-) progeroid mice but shortens it in a study of insecticide-susceptible A. arabiensis. Independent labs report both increased and decreased cellular senescence in cells; one group reports human associations, including lower mortality in women but no clear mortality link in men. A paper declares ties to Lumos Pharma.

100 findings in 56 papers from 1989 to 2026, 5 of them since April 2026

The findings reach people, from one lab or study; independent labs found the same change in cells. 40 independent labs in 17 countries; 1 trial, none about aging.

“suppressed pulsatile GH secretion (P = 0.003), burst mass (P = 0.025), burst number (P = 0.005)”
Testosterone supplementation in older men restrains insulin-like growth factor's dose-dependent feedback inhibition of pulsatile growth hormone secretionThe Journal of clinical endocrinology and metabolism2008doi:10.1210/jc.2008-1516

6 of its findings point the other way.

Cells: replicated by independent labs. Worms or flies, mice and humans: a single group.
  • 40 independent labs in 17 countries
  • 6 findings against
  • 1 trial, none about aging
  • Funders: National Institutes of Health and others
  • 2 of 89 findings with company ties
  • Human trial2
  • Humans13
  • Animals37
  • Model organisms1
  • Cells8
  • In silico1

Studies in people

1 study gave insulin-like growth factor 1 to people and measured what changed.

What changedDesignPeopleSource

down: Decreases pulsatile growth hormone secretion

Randomized trial24 peopleMen50 to 75 yearsOlder adults; exogenous recombinant IGF-I injectionThe Journal of clinical endocrinology and metabolism, Nov 4, 2008

What did studies of insulin-like growth factor 1 find?

79

Studies of insulin-like growth factor 1 measured 79 outcomes; the most studied are cellular senescence (7 studies), lifespan (3) and autophagy (2).

Cellular senescence

upin cells2upin human cells2downin cells1downin mice1+1

7 studies
  1. Insulin-like growth factor 1 decreases cellular senescence in mice (peritoneal fibrosis).

    “IGF1 supplementation with M2-Mφ supernatants or exogenous IGF1 alleviated mesothelial cell senescence and decreased fibrotic responses in PF mice.”

    Animalsperitoneal fibrosisM2-Mφ supernatants or exogenous IGF1mesothelial cell

    Asiaticoside alleviates mesothelial cell senescence and peritoneal fibrosis by targeting macrophage-mesothelial communication in single-cell peritoneal landscape

    Phytomedicine : international journal of phytotherapy and phytopharmacology

  2. Insulin-like growth factor 1 increases cellular senescence in human cells.

    “the cells cultured with old-age human serum or IGF-1 showed lower POLD1 expression and more pronounced senescence characteristics”

    Cells2BS cells

    IGF-1 Accelerates Cell Aging by Inhibiting POLD1 Expression

    Biomedical and environmental sciences : BES

  3. Insulin-like growth factor 1 induces cellular senescence in cells.

    “prolonged IGF1 treatment leads to the establishment of a premature senescence phenotype”

    Cellsprolonged

    Long-Term IGF1 Stimulation Leads to Cellular Senescence via Functional Interaction with the Thioredoxin-Interacting Protein, TXNIP

    Cells

  4. Insulin-like growth factor 1 induces cellular senescence in cells (alveolar epithelial cells, with enhanced core fucosylation).

    “We also showed that IGF1 could induce AECs senescence with enhanced CF in vivo and in vitro.”

    Cellsalveolar epithelial cells, with enhanced core fucosylation

    Regulation of the IGF1 signaling pathway is involved in idiopathic pulmonary fibrosis induced by alveolar epithelial cell senescence and core fucosylation

    Aging

  5. Insulin-like growth factor 1 decreases cellular senescence in cells (long-term cultured aortic smooth muscle cells).

    “We found that IGF-1 decreased cell senescence, prevented DNA telomere shortening”

    Cellslong-term cultured aortic smooth muscle cells

    Insulin-Like Growth Factor I Prevents Cellular Aging via Activation of Mitophagy

    Journal of aging research

  6. Insulin-like growth factor 1 induces cellular senescence in mice.

    “IGF-I induced cellular senescence in HSCs in vitro and in vivo.”

    Animalsliver

    IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner

    Scientific reports

  7. Insulin-like growth factor 1 increases cellular senescence in human cells.

    “which is accompanied by an accumulation of senescent cells”

    Cellsquiescent human fibroblasts14 days

    Long-term IGF-I exposure decreases autophagy and cell viability

    PloS one

More on Cellular senescence

Lifespan

downin A. arabiensis1downin L. animals1upin mice1

3 studies
  1. Insulin-like growth factor 1 shortens lifespan in L. animals.

    “In laboratory animals, the effects of IGF-1 on growth- and development (positive), reproduction (positive), and longevity (negative) are well established.”

    Review

    Insulin-like growth factor 1 of wild vertebrates in a life-history context

    Molecular and cellular endocrinology

  2. Insulin-like growth factor 1 shortens lifespan in the insecticide susceptible strain (SENN).

    “IGF elicited the same response in the susceptible strain”

    Model organismsin the insecticide susceptible strain (SENN)

    The effects of ingestion of hormonal host factors on the longevity and insecticide resistance phenotype of the major malaria vector Anopheles arabiensis (Diptera: Culicidae)

    PloS one

  3. Insulin-like growth factor 1 extends lifespan in Zmpste24(-/-) progeroid mice.

    “recombinant IGF-1 treatment restores the proper balance between IGF-1 and GH in Zmpste24(-/-) mice, delays the onset of many progeroid features, and significantly extends the lifespan”

    Animalsin Zmpste24(-/-) progeroid micerecombinant

    Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function

    Proceedings of the National Academy of Sciences of the United States of America

Autophagy

downin human cells1downin mice1

2 studies
  1. Insulin-like growth factor 1 decreases autophagy in mice (co-treatment with nicotinamide).

    “exogenous IGF1 counteracts nicotinamide-induced autophagy”

    Animalsco-treatment with nicotinamideexogenousheart

    NAD⁺ repletion restores cardioprotective autophagy and mitophagy in obesity-associated heart failure by suppressing excessive trophic signaling

    Autophagy

  2. Insulin-like growth factor 1 decreases autophagy in human cells.

    “a reduction in autophagy in the long-term IGF-I treated cultures”

    Cellsquiescent human fibroblasts14 days

    Long-term IGF-I exposure decreases autophagy and cell viability

    PloS one

More on Autophagy

Oxidative damage to lipids

no changein P. biarmicus1upin P. biarmicus1

1 study
  1. Insulin-like growth factor 1 showed no clear effect on oxidative damage to lipids in P. biarmicus (captive bearded reedlings under semi-natural conditions).

    “while no treatment effect was apparent in females.”

    Animalscaptive bearded reedlings under semi-natural conditionsslow-release biodegradable microspheresfemales

    IGF-1 induces sex-specific oxidative damage and mortality in a songbird

    Oecologia

  2. Insulin-like growth factor 1 increases oxidative damage to lipids in P. biarmicus (captive bearded reedlings under semi-natural conditions).

    “Oxidative damage to lipids showed marked sexual differences: it significantly increased the day after the manipulation in treated males”

    Animalscaptive bearded reedlings under semi-natural conditionsslow-release biodegradable microspheresone day post-treatmentmales

    IGF-1 induces sex-specific oxidative damage and mortality in a songbird

    Oecologia

Auditory function

upin mice1

1 study
  1. Insulin-like growth factor 1 improves auditory function in mice (exogenous administration) (partially restored).

    “Conversely, exogenous IGF-1 or SLC25A33 overexpression attenuated these effects and partially restored auditory function.”

    Animalsexogenous administrationexogenous

    IGF-1 and SLC25A33 preserve cochlear blood barrier integrity in aged mice

    Aging cell

Age-associated behavioral impairments

downin mice1

1 study
  1. Insulin-like growth factor 1 decreases age-associated behavioral impairments in mice (chronic intra-PFC infusion in aged mice).

    “chronic intra-PFC infusion of IGF1 alleviated age-associated behavioral impairments in aged mice”

    Animalschronic intra-PFC infusion in aged miceprefrontal cortex

    Cell-type-dependent decline of IGF1 and IGF1R in the prefrontal cortex contributes to age-related behavioral changes

    Frontiers in aging neuroscience

Peritoneal fibrosis

downin mice1

1 study
  1. Insulin-like growth factor 1 decreases peritoneal fibrosis in mice (peritoneal fibrosis).

    “IGF1 supplementation with M2-Mφ supernatants or exogenous IGF1 alleviated mesothelial cell senescence and decreased fibrotic responses in PF mice.”

    Animalsperitoneal fibrosisM2-Mφ supernatants or exogenous IGF1peritoneum

    Asiaticoside alleviates mesothelial cell senescence and peritoneal fibrosis by targeting macrophage-mesothelial communication in single-cell peritoneal landscape

    Phytomedicine : international journal of phytotherapy and phytopharmacology

More on Peritoneal fibrosis

FOS expression

upin mice1

1 study
  1. Insulin-like growth factor 1 increases FOS expression in mice.

    “mice receiving systemic IGF-1 showed increased c-fos expression in VTA neurons”

    Animalsventral tegmental area neuron

    Interoceptive Information of Physical Vigor Through Circulating Insulin-Like Growth Factor 1

    FASEB bioAdvances

More on FOS expression

Spontaneous running

upin mice1

1 study
  1. Insulin-like growth factor 1 increases spontaneous running in mice (LID mice with low serum IGF-1).

    “Reduced activity normalized after sustained systemic IGF-1 treatment.”

    AnimalsLID mice with low serum IGF-1sustainedfemales

    Interoceptive Information of Physical Vigor Through Circulating Insulin-Like Growth Factor 1

    FASEB bioAdvances

Cognitive function

upin rodents1

1 study
  1. Insulin-like growth factor 1 improves cognitive function in rodents (preclinical rodent models and transgenic models of IGF-1).

    “increased IGF-1 improves cognition in a variety of behavioral paradigms”

    Reviewpreclinical rodent models and transgenic models of IGF-1

    Insulin-like growth factor-1 and cognitive health: Exploring cellular, preclinical, and clinical dimensions

    Frontiers in neuroendocrinology

Pulsatile growth hormone secretion

downin humans1

1 study
  1. Insulin-like growth factor 1 decreases pulsatile growth hormone secretion in humans (exogenous recombinant IGF-I injection).

    “suppressed pulsatile GH secretion (P = 0.003), burst mass (P = 0.025), burst number (P = 0.005)”

    Human trialexogenous recombinant IGF-I injectionrecombinant humanmalesn = 24

    Testosterone supplementation in older men restrains insulin-like growth factor's dose-dependent feedback inhibition of pulsatile growth hormone secretion

    The Journal of clinical endocrinology and metabolism

More on Pulsatile growth hormone secretion

All 79

What is insulin-like growth factor 1 linked with?

10

Studies link insulin-like growth factor 1 with 10 measures, among them mortality, gait variability and gait asymmetry index.

Mortality

downin humans1upin mice1HR 0.4

2 studies
  1. Insulin-like growth factor 1 is linked with a lower risk of mortality in humans (per log2-transformed IGF1 doubling, adjusted for age and eGFR) (HR 0.40 (95% CI 0.24–0.65) per IGF1 doubling; p < 0.001).

    “low IGF1 levels associate with an increased risk of all-cause mortality in female RTR”

    Humansper log2-transformed IGF1 doubling, adjusted for age and eGFRmedian follow-up 5.4 yearsfemalesn = 277

    Female Specific Association of Low Insulin-Like Growth Factor 1 (IGF1) Levels with Increased Risk of Premature Mortality in Renal Transplant Recipients

    Journal of clinical medicine

  2. Insulin-like growth factor 1 is associated with mortality in KO-HIT mice lacking tissue Igf1 expression, both sexes.

    “increases in serum IGF-1 levels were associated with increased levels of lipid peroxidation products in serum and increased mortality rate at 18 months of age”

    Animalsin KO-HIT mice lacking tissue Igf1 expression, both sexes

    Increased serum IGF-1 levels protect the musculoskeletal system but are associated with elevated oxidative stress markers and increased mortality independent of tissue igf1 gene expression

    Aging cell

Gait variability

downin humans1

1 study
  1. Insulin-like growth factor 1 is associated with gait variability in humans.

    “lower CVs for swing time, thigh acceleration, landing control force, and toe-off angle”

    Humanscoefficient of variation of swing time, thigh acceleration, landing control force and toe-off anglen = 642

    Associations of insulin-like growth factor-1 with gait vigor, symmetry, and stability metrics measured by wearable sensors in older adults

    BMC geriatrics

Gait asymmetry index

downin humans1

1 study
  1. Insulin-like growth factor 1 is associated with gait asymmetry index in humans (asymmetry index for thigh acceleration and landing control force).

    “Higher IGF-1 levels were associated with lower AIs for thigh acceleration and landing control force”

    Humansasymmetry index for thigh acceleration and landing control forcen = 642

    Associations of insulin-like growth factor-1 with gait vigor, symmetry, and stability metrics measured by wearable sensors in older adults

    BMC geriatrics

Gait speed

upin humans1

1 study
  1. Insulin-like growth factor 1 is associated with gait speed in humans (per 1-SD increase in IGF-1, after adjustment for covariates) (β = 1.105, P = 0.025 per 1-SD increase in IGF-1).

    “gait speed (β = 1.105, P = 0.025)”

    Humansper 1-SD increase in IGF-1, after adjustment for covariatesn = 642

    Associations of insulin-like growth factor-1 with gait vigor, symmetry, and stability metrics measured by wearable sensors in older adults

    BMC geriatrics

Multidimensional gait performance

upin humans1

1 study
  1. Insulin-like growth factor 1 is associated with multidimensional gait performance in humans after adjustment for covariates; community-dwelling older adults.

    “Higher circulating IGF-1 levels are associated with better multidimensional gait performance in community-dwelling older adults.”

    Humansafter adjustment for covariates; community-dwelling older adultsn = 642

    Associations of insulin-like growth factor-1 with gait vigor, symmetry, and stability metrics measured by wearable sensors in older adults

    BMC geriatrics

Longevity

mixedin humans1

1 study
  1. Insulin-like growth factor 1 is associated with longevity in humans.

    “identifying cholesterol levels, immune cell traits and insulin-like growth factor-1 (IGF1) as associated with longevity”

    Humans

    Genetic and molecular factors underlying human longevity and epigenetic aging

    npj aging

Executive function

upin humans1

1 study
  1. Insulin-like growth factor 1 is associated with executive function in prediabetes (β = 0.115 [0.028, 0.202], p = 0.010).

    “Higher IGF-1 concentrations were associated with better executive performance in individuals with prediabetes (β = 0.115 [0.028, 0.202], p = 0.010), but not in individuals with normoglycemia or T2DM.”

    Humansin prediabetesn = 512

    Insulin-like growth factor-1 and cognition in normoglycemia, prediabetes, and type 2 diabetes mellitus

    Psychoneuroendocrinology

Lipid peroxidation products

upin mice1

1 study
  1. Insulin-like growth factor 1 is associated with lipid peroxidation products in KO-HIT mice lacking tissue Igf1 expression.

    “increases in serum IGF-1 levels were associated with increased levels of lipid peroxidation products in serum”

    Animalsin KO-HIT mice lacking tissue Igf1 expression

    Increased serum IGF-1 levels protect the musculoskeletal system but are associated with elevated oxidative stress markers and increased mortality independent of tissue igf1 gene expression

    Aging cell

More on Lipid peroxidation products

Estrogen receptor-positive breast cancer

upin humans1OR 1.38

1 study
  1. Insulin-like growth factor 1 is linked with a higher risk of estrogen receptor-positive breast cancer in humans (OR 1.38 (95% CI 1.14-1.68)).

    “The ORs for a difference in IGF1 concentration between the highest and lowest fifth were 1.38 (95% CI 1.14-1.68) for oestrogen-receptor-positive tumours”

    Humansfemales

    Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies

    The Lancet. Oncology

More on Estrogen receptor-positive breast cancer

Breast cancer

upin humans1OR 1.28

1 study
  1. Insulin-like growth factor 1 is linked with a higher risk of breast cancer in humans (OR 1.28 (95% CI 1.14-1.44)).

    “The OR for breast cancer for women in the highest versus the lowest fifth of IGF1 concentration was 1.28 (95% CI 1.14-1.44; p<0.0001).”

    Humansfemales

    Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies

    The Lancet. Oncology

More on Breast cancer

Has insulin-like growth factor 1 been tested in people?

0 of 1 about aging

Yes: 2 trials and 13 observational studies in people have been published, and 1 trial is registered.

In trials

  • Autistic disorder

    Phase 2Results posted1 trial

Trial sponsors

Funding

2 grants since 2019

National Heart, Lung, and Blood Institute$2.7MJapan Society for the Promotion of Science¥4.3M

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 0Jan 2026: 2Feb 2026: 1Mar 2026: 1Apr 2026: 1May 2026: 1Jun 2026: 1Jul 2026: 3Aug 2026: 2Sep 2026: 1Oct 2026: 1Nov 2026: 014 papers in 12 months

See all 99 papers on insulin-like growth factor 1